COLLINSON
27.6.2024 10:01:32 CEST | Business Wire | Press release
Collinson, a global leader in travel experience and loyalty programmes, has announced a strategic partnership with World Nomads, the global travel insurance provider, including the launch of a new Annual Multi-Trip (AMT) product in the UK & Ireland.
The new product range will enhance the customer experience with the addition of increased coverage limits and new benefits that apply to both annual and single-trip policies, as well as innovative parametric service, SmartDelayTM. These enhancements ensure that travellers are better protected against a wider range of travel-related issues and unexpected flight delays or cancellations.
As part of the partnership, Collinson will be responsible for underwriting the AMT product as well as providing World Nomad customers with the use of its new parametric product SmartDelay.
SmartDelay is a real-time, parametric product which provides customers with a range of benefits in the event of a flight disruption, for example, providing access to over 1500 airport lounges or alternative benefits such as spa, sleep pods and restaurant discounts for travellers experiencing flight delays. SmartDelay also gives traveller access to Air Doctor, which connects travellers with private doctors and medical advice in destinations where public health services may be overstretched and/or unable to treat international travellers.
This new partnership supports Collinson’s UK and European growth ambitions, allowing the company to underwrite business for World Nomads in the UK, Ireland, Germany, Denmark, Belgium and Holland, with more to follow.
Greg Lawson, Head of Travel Insurance at Collinson, said: “Given both Collinson and World Nomads are established and respected brands by travellers globally, our collaboration in developing products that deliver above and beyond what today’s travellers demand from their travel insurance, demonstrates our commitment in offering fair value, flexibility and choice. The synergies of our companies make our partnership stronger, given Collinson’s experience as a renowned travel underwriter and World Nomad’s commitment to offer innovative travel insurance. It’s a great time to bring exciting products to the travel market to drive our shared UK and European growth ambitions.”
World Nomads’ AMT policy offers comprehensive and cost-effective coverage for frequent international and domestic travellers, allowing for multiple trips within a one-year period under a single policy. Additionally, a higher age limit (up to 69 years) and free coverage for children (aged under 18) when travelling with adult relatives or friends applies, making the AMT policy ideal for multigenerational travel.
Jonathan Frankham, General Manager, UK and Europe, World Nomad, said: “Both the introduction of the AMT product and the integration of Collinson as World Nomads’ new underwriters reflect our unwavering commitment to providing adventurous travellers with the most comprehensive and innovative coverage available. We are thrilled to offer an enhanced travel insurance experience that addresses the unique needs of today's travellers. With features like Air Doctor and SmartDelay, our travellers can tackle today's most common travel challenges with confidence, enjoying seamless access to medical care and luxurious airport lounges during delays.”
Issued by Rein4ce on behalf of Collinson
About Collinson
Collinson Insurance: specialty lines, travel and accident & health insurance, includes underwriting capacity, insurance products and access to expert TPAs in the UK and Europe. Our deep understanding of loyalty and membership programmes enables us to offer true differentiation, so clients have confidence in our partnership to deliver growth. SmartDelay is a parametric service that ensures airline passengers who have registered their flight are given access to an airport lounge or alternative benefit, in the event of a flight delay or cancellation. Priority Pass is the world’s original and market-leading airport experiences programme. We provide travellers with access to over 1,500 airport lounges and travel experiences in over 700 airports in 145 countries.
About World Nomads
World Nomads is a fast-growing, global travel insurance company. We provide inspirational stories, safety tips and specialised travel insurance for adventurous and independent travellers. Our online travel insurance offers cover to travellers from more than 100 countries and allows you to buy and claim online, 24/7, even while already traveling.
Our travel insurance focuses on what we believe is important to travellers: emergency medical and evacuation costs, baggage, trip cancellation, trip delay and trip interruption costs. We also offer cover for more than 200 adventure sports and activities, plus tech and gear. Our policies are underwritten by a suite of specialist travel insurers that provide 24/7 emergency assistance, customer service and claims support, making us a top choice for many of the world's leading adventure, independent and youth travel brands.
World Nomads is a part of the nib Group which provides health and medical insurance to more than 1.5 million Australian and New Zealand residents. We also provide health insurance to more than 170,000 international students and workers in Australia and are Australia’s third-largest travel insurer and global distributor of travel insurance through our business nib Travel.
https://www.worldnomads.com/uk/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627952877/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom